In a double-blind, crossover study, 10 cirrhotic patients (Child B rating) with steatorrhoea (daily output of faecal fat > 8 g) and dyspepsia were placed on a controlled diet for 14 days. Patients then received 150 mg ursodeoxycholic acid (UDCA) or placebo twice daily for 14 days. Faecal fat excretion was reduced from 14.7 to 10.6 g/day by UDCA and dyspepsia symptom scores were also reduced. Serum aspartate aminotransferase concentrations declined significantly (P < 0.02) following UDCA treatment, whereas serum bile acid levels increased from 35 to 40.5 μM and the percentage of UDCA increased to 22%. It is concluded that UDCA may be useful for many of the symptoms present in patients with liver cirrhosis.
FosterPN, WyattJI, BullimoreDW: Gastric mucosa in patients with portal hypertension: prevalence of capillary dilation and Campylobacter pylori. J Clin Pathol1989; 42: 919–921.
2.
SacchettiC, CapelloM, RebecchiP: Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Dig Dis Sci1988; 33: 1281–1282.
3.
HofmannAF, BorgströmB: The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption. J Clin Invest1964; 43: 247–257.
4.
ThomsonABR, DietschyJM: Intestinal lipid absorption: major extracellular and intracellular events. In: Physiology of the Gastrointestinal Tract (JohnsonLR, ed). New York: Raven Press, 1981; pp 1147–1220.
5.
BadleyBWD, MurphyGM, BouchierIAD: Diminished micellar phase lipid in patients with chronic non-alcoholic liver disease and steatorrhea. Gastroenterology1970; 58: 781–789.
6.
LosowskiMS, WalkerBE: Liver disease and malabsorption. Gastroenterology1969; 56: 589–600.
7.
LinscheerWG: Malabsorption in cirrhosis. Am J Clin Nutr1970; 23: 488–492.
8.
MiettinenTA, SiuralaM: Micellar solubilization of intestinal lipids and sterols in gluten enteropathy and liver cirrhosis. Stand J Gastroenterol1971; 6: 527–535.
9.
WilsonFA, DietschyM: Approach to the malabsorption syndromes associated with disordered acid metabolism. Arch Intern Med1972; 130: 584–594.
10.
MiettinenTA: Lipid absorption, bile acids and cholesterol metabolism in patients with chronic liver disease. Gut1972; 13: 682–689.
11.
VlahcevicR, JuttijudataP, BellC: Bile acid metabolism in patients with cirrhosis. II. Cholic and chenodeoxycholic acid metabolism. Gastroenterology1972; 62: 1174–1181.
12.
AkashiY, MiyazakiH, YanagisawaJ: Bile acid metabolism in cirrhotic liver tissue – altered synthesis and impaired hepatic secretions. Clin Chim Acta1987; 168: 199–206.
13.
SchöelmerichJ, BecherMS, SchmidtK: Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties. Studies on isolated hepatocytes and lipid membrane vesicles. Hepatology1984; 4: 661–666.
14.
PouponR, ChretienY, PouponRE: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?Lancet1987; i: 834–836.
15.
LeuschnerU, FischerH, KurtzW: Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology1989; 97: 1268–1274.
16.
PughRNH, Murray-LyonM, DawsonJL: Transections of oesophagus for bleeding oesophageal varices. Br J Surg1973; 60: 645–649.
17.
TalleyNJ, McNeilD, PiperDW: Discriminant value of dyspeptic symptoms: a study of the clinical presentation of 221 patients with dyspepsia of unknown cause, peptic ulceration and cholelithiasis. Gut1987; 28: 40–46.
18.
BolinDW, KingRP, KlostermanEW: A simplified method for the determination of chromic oxide (Cr203) when used as an index substance. Science1952; 116: 634–635.
19.
SalvioliG, LugliR, PradelliIM: Cholesterol absorption and sterol balance in normal subjects receiving dietary fiber or ursodeoxycholic acid. Dig Dis Sci1985; 30: 301–307.
20.
ThompsonJB, SuCK, RingroneRE: Fecal triglycerides II. Digestive versus absorptive steatorrhea. J Lab Clin Med1969; 73: 521–530.
21.
Van de KamerJH, HuininkHB, WeyersHA: Rapid method for the determination of fat in feces. J Biol Chem1949; 177: 347–355.
22.
KirkRE: Multiple Comparison Tests. In: Experimental Design: Procedure for the Behavioral Sciences (BrooksS, ed). Belmond: Cole Publishing, 1968; pp 90–91.
23.
BaraonaE, OrregoH, FernándezO: Absorptive function of the small intestine in liver cirrhosis. Am J Dig Dis1962; 7: 318–319.
24.
MiuraS, AsakuraH, KobayashiK: Lymphatic role in the pathogenesis of fat malabsorption in liver cirrhosis in rats. Dig Dis Sci1982; 27: 1030–1035.
25.
RosE, Garciá-PugésA, ReixachM: Fat digestion and exocrine pancreatic function in primary biliary cirrhosis. Gastroenterology1984; 87: 180–187.
26.
WestergaardH: Duodenal bile acid concentration in fat malabsorption syndromes. Scand J Gastroenterol1977; 12: 115–122.
27.
BarbaraL, CamilleriM, CorinaldesiR: Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci1989; 34: 1272–1276.
28.
StefaniwskyAB, TintGS, SpeckJ: Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology1985; 89: 1000–1004.
29.
LeuschnerU, LeuschnerM, SieratzkiJ: Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci1985; 30: 642–649.
BellentaniS, TabarroniG, BarchiT: Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial. J Hepatol1989; 8: 7–12.
32.
GaettiE, SalvioliG, GualdiGL: Effect of bile salts (BS) on red blood cell (RBC) membrane: a method to evaluate their membrane-damaging effect (Abstract). Proceedings of International Meeting on Pathochemistry, Pathophysiology and Pathomechanics of the Biliary System, Bologna, 1988; p. 13.
33.
OwenOE, ReichleFA, MozzoliMA: Hepatic, gut and renal substance flux rates in patients with hepatic cirrhosis. J Clinlnvest1981; 68: 240–252.
